• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pulmatrix completes patient dosing for inhaled migraine treatment

September 26, 2022 By Sean Whooley

Pulmatrix iSperse migraine therapy
iSperse technology. [Image from Pulmatrix]
Pulmatrix (Nasdaq:PULM) announced today that all subjects completed dosing in a trial of its orally inhaled migraine treatment.

Lexington, Massachusetts-based Pulmatrix is evaluating PUR3100 in a Phase 1 trial using the patented iSperse technology. All subjects completed dosing of the novel orally inhaled formulation of dihydroergotamine (DHE). The company expects Phase 1 data in the fourth quarter of this year.

The trial features a double-dummy, double-blinded design. It assesses the safety, tolerability and pharmacokinetics of three dose groups of inhaled PUR3100 with intravenous (IV) placebo.

Pulmatrix is comparing its treatment to a single dose of IV DHE (DHE mesylate injection) with inhaled placebo. The evaluation includes 26 healthy subjects with at least six subjects in each of the four groups.

The company aims to address the limited options of administration for DHE. Currently, according to a news release, it requires intravenous administration in the emergency department or poorly tolerated nasal spray adminsitration.

Combining convenience with efficacy and tolerability

“We believe that both the convenience and potential efficacy and tolerability profile of an inhaled DHE will allow for significant adoption, particularly among those who cannot obtain relief from current prescription medications,” said Pulmatrix CEO Ted Raad. “We look forward to advancing PUR3100 to potentially be a best-in-class product for this debilitating disease.”

Pulmatrix designed iSperse to improve therapeutic delivery to the lungs. It maximizes local concentrations and reduces systemic side effects to improve patient outcomes.

“We are evaluating a proprietary formulation of inhaled PUR3100 for the potential treatment of acute migraine – an underserved neurological disease for which patients are in great need of different therapeutic options,” added Dr. Margaret Wasilewski, Pulmatrix CMO. “Pulmatrix’s iSperse technology enables a formulation of DHE that can be immediately self-administered, and thereby, offers the potential for an optimized treatment for acute migraine patients in terms of timing and convenience of administration.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Pulmatrix Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS